DIARNAGNOSIS: A novel platform for the direct profiling of circulating cell-free ribonucleic acids in biofluids
Conventional cancer biopsies rely on invasive methods to take samples from a tumour’s tissues. The sample is used for histological analysis for the clinical diagnosis, and for identification of prognostic and therapeutic targets. Circulating cell-free ribonucleic acids (ccfRNAs) have opened the door to a non-invasive alternative – liquid biopsy. However, despite extensive academic and clinical research, ccfRNAs have not yet entered the field of clinical diagnostics. This is in part because the current analytical methods are unsatisfactory, meaning that ccfRNA detection remains challenging, costly, and based on elaborate multi-step sample preparations. The EU-funded diaRNAgnosis project brings together a pan-European, multidisciplinary and intersectoral team to deliver a new platform for the direct quantitative measurement of ccfRNA signatures that are specifically and overexpressed in testicular germ cell tumour and prostate cancer.
- Researcher:Rosario María Sánchez Martín
- Group: TECe18-NANOCHEMBIO
- Center: University of Granada
- Rol in the project: Participants
- Duration: 2021 – 2024
Página web del proyecto: https://www.diarnagnosis.com/